A Safety and Efficacy Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With DissolveAV

Inclusion Criteria: 1. Age 18-75 years (inclusive), male or female; 2. Patients with mature AVF/AVG and at least one successful hemodialysis session; 3. Target lesion located in the AVF/AVG reflux vein (excluding the feeding artery and central vein); 4. With hemodynamically significant AVF/AVG stenosis and meeting two of the following conditions (A \& B) A. ≥ 50% stenosis of the target lesion as assessed by angiography B. Presence of at least one of the following (as defined in the NKF-K/DOQI guidelines) 1)Significantly elevated venous pressure during dialysis 2)Unexplained decrease in dialysis dose 3)Decrease in pump-controlled blood flow; 5. De novo or restenotic target lesion consisting of one or more tandem lesions, and with a visual reference vessel diameter of 4.0-8.0 mm and a total length ≤ 40 mm for the target lesion; 6. All non-target lesions must have \<50% stenosis without clinical indication for treatment. 7. Patients who have signed the informed consent form. Exclusion Criteria: 1. Patients who are participating in another clinical trial of a drug product or medical device; 2. Patients previously enrolled in this trial; 3. Women of childbearing age with a non-negative pregnancy test prior to surgical procedure, or lactating women; 4. Patients treated with major surgeries (e.g., open-heart surgery, cranial surgery) within 30 days prior to enrollment in the study; 5. Immature AVF/AVG (not subjected to dialysis; this vascular access has not been subjected to a single successful dialysis due to insufficient inner diameter that prevents successful puncture and results in inadequate blood flow); 6. Calcified lesions that are not expected to be dilated with a balloon; 7. AVF/AVG implanted with a stent; 8. AVF/AVG lesions previously treated with DCB; 9. Target lesions located at the venous anastomosis of AVF/AVG; 10. Impaired central venous reflux ; 11. Presence of a stenotic lesion in the artery that severely interferes with blood flow; 12. Patients with known allergy or intolerance to paclitaxel or contrast agent; 13. Patients with a life expectancy of less than 1 year; 14. Patients with concomitant systemic lupus erythematosus (SLE), ANCA-associated small vessel vasculitis; 15. Patients with a history of coagulopathy or thrombocytopenic purpura; 16. Patients treated with or scheduled to be treated with renal transplant or who have switched to peritoneal dialysis; 17. Vascular access infections or active systemic infections; 18. Presence of other medical conditions considered ineligible for the study as assessed by the investigator.